Pacira BioSciences, Inc. (PCRX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 70M 140M 210M Q3 '21: 127.7M Q4 '21: 159.2M Q1 '22: 158M Q2 '22: 169.4M Q3 '22: 167.5M Q4 '22: 172M Q1 '23: 160.3M Q2 '23: 169.5M Q3 '23: 163.9M Q4 '23: 181.2M Q1 '24: 167.1M Q2 '24: 178M Q3 '24: 168.6M Q4 '24: 187.3M Q1 '25: 168.9M Q2 '25: 181.1M Q3 '25: 179.5M Q4 '25: 196.9M Q1 '26: 177.4M Q2 '26: 192.4M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit Quarterly

0 60M 120M 180M Q3 '21: 93.1M Q4 '21: 120.2M Q1 '22: 121.9M Q2 '22: 118.8M Q3 '22: 116.8M Q4 '22: 110M Q1 '23: 111.3M Q2 '23: 121.3M Q3 '23: 124.2M Q4 '23: 133.6M Q1 '24: 119.7M Q2 '24: 133.8M Q3 '24: 129.7M Q4 '24: 147.4M Q1 '25: 134.6M Q2 '25: 140.2M Q3 '25: 145.2M Q4 '25: 156.6M Q1 '26: 141M Q2 '26: 148.2M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income Quarterly

-150M -100M -50M 0 50M 100M 150M Q2 '21: 34.8M Q3 '21: 31.4M Q4 '21: 4.2M Q1 '22: 17.4M Q2 '22: 31.2M Q3 '22: 21.3M Q1 '23: -3.1M Q2 '23: 39.9M Q3 '23: 17.7M Q4 '23: 33.2M Q1 '24: 13.2M Q2 '24: 28.2M Q3 '24: -139.5M Q4 '24: 24.7M Q1 '25: 2M Q2 '25: 8.5M Q3 '25: 6.4M Q4 '25: 2.3M Q1 '26: 6.9M Q2 '26: 4.3M Q3 '21 Q2 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-150M -100M -50M 0 50M 100M 150M Q2 '21: 19.1M Q3 '21: 17.7M Q1 '22: 6.8M Q2 '22: 19.9M Q3 '22: -693K Q4 '22: -10.1M Q1 '23: -19.5M Q2 '23: 25.8M Q3 '23: 10.9M Q4 '23: 24.9M Q1 '24: 9M Q2 '24: 18.9M Q3 '24: -143.5M Q4 '24: 16M Q1 '25: 4.8M Q2 '25: -4.8M Q3 '25: 5.4M Q4 '25: 1.6M Q1 '26: 2.9M Q2 '26: 4.7M Q3 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue Quarterly

0 25M 50M 75M Q3 '21: 34.7M Q4 '21: 39M Q1 '22: 36.1M Q2 '22: 50.6M Q3 '22: 50.7M Q4 '22: 61.9M Q1 '23: 49M Q2 '23: 48.2M Q3 '23: 39.8M Q4 '23: 47.7M Q1 '24: 47.4M Q2 '24: 44.3M Q3 '24: 38.9M Q4 '24: 39.9M Q1 '25: 34.3M Q2 '25: 40.9M Q3 '25: 34.3M Q4 '25: 40.3M Q1 '26: 36.4M Q2 '26: 44.2M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Cash Flow Quarterly

0 25M 50M 75M Q3 '21: 60.3M Q4 '21: 23.2M Q1 '22: 30.8M Q2 '22: 29.8M Q3 '22: 42.7M Q4 '22: 42M Q1 '23: 19.1M Q2 '23: 43.5M Q3 '23: 44.4M Q4 '23: 47.6M Q1 '24: 49.1M Q2 '24: 53.2M Q3 '24: 53.9M Q4 '24: 33.1M Q1 '25: 35.5M Q2 '25: 12M Q3 '25: 60.8M Q4 '25: 43.7M Q1 '26: 25.7M Q2 '26: 57.5M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

0 20M 40M 60M Q3 '21: 47.2M Q4 '21: 14M Q1 '22: 23.1M Q2 '22: 18.1M Q3 '22: 37.5M Q4 '22: 36.5M Q1 '23: 12.6M Q2 '23: 40.1M Q3 '23: 41M Q4 '23: 45.8M Q1 '24: 46.3M Q2 '24: 51.6M Q3 '24: 49.8M Q4 '24: 31M Q1 '25: 26.9M Q2 '25: 9.3M Q3 '25: 57M Q4 '25: 43.5M Q1 '26: 23M Q2 '26: 56.1M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 20M 40M 60M Q1 '20: 42.8M Q2 '20: 42.2M Q3 '20: 44.3M Q1 '21: 46M Q2 '21: 45.6M Q3 '21: 45.5M Q1 '22: 46.4M Q2 '22: 52.5M Q3 '22: 45.8M Q1 '23: 45.9M Q2 '23: 52.1M Q3 '23: 52.1M Q1 '24: 52.2M Q2 '24: 50.5M Q3 '24: 46.1M Q1 '25: 46.5M Q2 '25: 45.5M Q3 '25: 44.5M Q1 '26: 40.9M Q2 '26: 40.3M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-3.00 -1.50 0.00 1.50 3.00 4.50 Q3 '20: 2.84 Q4 '20: 3.28 Q1 '21: 3.32 Q2 '21: 3.91 Q3 '21: 1.36 Q4 '22: 0.34 Q1 '23: -0.24 Q2 '23: -0.13 Q3 '23: 0.12 Q4 '23: 0.83 Q1 '24: 1.45 Q2 '24: 1.33 Q3 '24: -2.01 Q4 '24: -2.15 Q1 '25: -2.24 Q2 '25: -2.74 Q3 '25: 0.49 Q4 '25: 0.15 Q1 '26: 0.12 Q2 '26: 0.35 Q4 '20 Q3 '21 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.